Science Sub-journal: Old medicine new multi-sclerosis therapy can also cure brain cancer

Recently, a team of Professors Of The University of California, San Diego, combined Sanofi's drug, Aubagio (teriflunomide), for the treatment of multiple sclerosis (MS), with the targeted tumor drug BKM-120 (buparlisib) to study the therapeutic effects of GBM miceCompared to a single targeted cancer treatment, combination therapy can improve survival in mice more effectively and inhibit tumor growth, which is expected to improve clinical outcomes in PATIENTs with GBMThe work is published in Science Translational Medicinetraditional radiotherapy and chemotherapy techniques can kill most GBM cells, but cannot destroy glioblastoma stem cells (GSCs), which can lead to repeated attacks of brain tumorsProfessor Jeremy NRich's team believes that understanding metabolic changes in GSC is important for developing new treatment strategiesThey found that the synthesis of radon in GSC increased significantly, and that the substance was an important component of nucleic acidsThey also took genomic data samples from hundreds of GBM patients from six different databases and found a significant reduction in patient survival ratesthe reforest, the author envisions using Agiouba inhibitory radon synthasase to block the synthesis of radon, thus achieving the effect of complementary treatment of GBMThey transplanted GBM from the human body into mice and tested the effects of two targeted tumor drugsOne is the GBM drug BKM-120 (buparlisib), which is deficient in PTEN enzyme, and the other is the epidermal growth factor (EGFR) tyrosine kinase inhibitor lapatinib, which can be used to treat tumors with mutations in the EGFR geneThe former showed better therapeutic outcomes, and using BKM-120 alone reduced brain tumors in mice to a certain extent than placebo and Aubagio aloneBut when Aubagio was combined with BKM-120, the brain tumor was significantly reduced and the survival of the mice was further prolongedcomparison of the effects of single-handed administration with combination therapy (Photo: Source: Supplied, 2)professor Jeremy NRich, author of the study, said Aubagio has been clinically proven as a safe drug for humansHowever, although the work was conducted using GBM organizations from humans, but has not yet been tested in the human body environment, how the immune system responds is still unknown, and further clinical trials are needed to explore the safety and efficacy of the combination therapy References sanofi's MS Drug May Be Effective in Treating Brain Cancer Retrieved Aug 13, 2019, from https:// Targeting Pyrimidine Synthesis Accentuates Molecular Therapy Response in Glioblastoma Stem Cells Sci Transl Med., DOI: 10.1126/scitranslmed.aau4972